Bicycle Therapeutics - BCYC Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.

13 brokerages have issued 12 month price targets for Bicycle Therapeutics' stock. Their BCYC share price forecasts range from $30.00 to $80.00. On average, they anticipate the company's stock price to reach $52.64 in the next year. This suggests a possible upside of 82.6% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.

Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 2.6% and is now trading at $28.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BCYC earnings forecast.

Bicycle Therapeutics plc (NASDAQ:BCYC) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative net margin of 669.65% and a negative trailing twelve-month return on equity of 31.56%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Bicycle Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.44%), Harbor Capital Advisors Inc. (0.08%), TD Asset Management Inc (0.08%), AtonRa Partners (0.06%), Simplex Trading LLC (0.00%) and Twelve Points Wealth Management LLC (0.02%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCYC stock can currently be purchased for approximately $28.82.

Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $855.67 million and generates $11.70 million in revenue each year. The company earns $-66,820,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

The company employs 119 workers across the globe.

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503.